Saudi Arabia Intravenous Solution Market Size and Share - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The Saudi Arabia intravenous solution market was valued at USD 495.14 Million in 2024 and is expected to grow at a CAGR of 6.50% , reaching USD 929.45 Million by 2034 . The market growth is driven by the rising chronic disease prevalence, and nutritional deficiencies are fueling steady demand for intravenous therapies in Saudi Arabia. The growing healthcare investments and preventive wellness adoption are further strengthening the country’s intravenous solutions market outlook.
Key Market Trends and Insights
The market is steadily evolving, supported by increasing hospital admissions, surgical procedures, and rising demand for advanced nutritional therapies. The market plays a modest yet important role globally, as Saudi Arabia contributed around 1.5% of the global intravenous solution market revenue during the historical period. The growing incidences of chronic illnesses, coupled with a higher prevalence of malnutrition in critically ill patients, are fueling demand for intravenous therapies. These factors are expected to strengthen market growth and enhance healthcare delivery outcomes. The market is expected to grow at a CAGR of 6.50% during the forecast period of 2025-2034 and attain a market value of USD 929.45 Million by 2034 .
Saudi Arabia Intravenous Solution Market Growth Drivers
Dedicated Infusion Clinics Bolstering Saudi Arabia IV Solution Market Expansion
Market drivers such as rising chronic disease rates and growing consumer wellness orientation are fueling demand for advanced IV therapies. For instance, in October 2024, IV ONE, Saudi Arabia’s first dedicated outpatient infusion therapy center, launched in Riyadh to serve chronic illness and nutrient-deficient patients. This facility offers personalized care delivered by specialists, integrated health systems, and faster clinical outcomes. Over the forecast period, this model is poised to elevate market value and adoption across the Kingdom by enhancing accessibility, improving treatment efficiency, and encouraging broader acceptance of intravenous solutions.
Saudi Arabia Intravenous Solution Market Trends
Major market trends include rise in foreign investments and emphasis on preventive healthcare adoption.
Foreign Investments Driving Saudi Arabia Intravenous Solution Market Growth
Rising healthcare infrastructure development and government support for local manufacturing are key drivers shaping the market. For instance, in January 2025, US-based Akkad Holdings announced a USD 200 million investment to establish an intravenous fluid production plant in King Abdullah Economic City, with operations expected after regulatory clearances within 18 months. This project, developed under Shamek IV Solutions, will address global IV shortages while boosting Saudi Arabia’s self-sufficiency and export capacity, significantly enhancing market growth prospects during the forecast period.
Rising Preventive Healthcare Focus Strengthening Saudi Arabia Intravenous Solution Market
The market is increasingly benefiting from the growing focus on preventive healthcare and wellness. With a rising prevalence of chronic diseases, nutritional deficiencies, and lifestyle-related conditions, demand for intravenous therapies is expanding beyond hospitals into outpatient and wellness settings. Consumers are adopting IV hydration and nutrient therapies for faster recovery, enhanced immunity, and preventive health maintenance. This shift toward proactive healthcare is expected to significantly drive market growth, broadening the application base for intravenous solutions in the forecast period.
Saudi Arabia Intravenous Solution Market Share
Total Parenteral Nutrition to Lead the Market by Type
Total parenteral nutrition is expected to hold the largest share of the Saudi Arabia intravenous solutions market, driven by its critical role in supporting patients unable to meet nutritional needs orally or enterally. It accounted for nearly 68% of market revenue during the historical period, underlining its dominance. The rising prevalence of chronic illnesses, surgical interventions, and malnutrition cases in hospitalized patients are further fueling demand. These factors position total parenteral nutrition as the primary growth driver across the country.
Leading Players in the Saudi Arabia Intravenous Solution Market
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Ajinomoto Health & Nutrition North America, Inc.
Ajinomoto Health & Nutrition is a division of the global Ajinomoto Group that develops, manufactures, and supplies amino acid-based products for pharmaceutical, nutraceutical, medical food, and wellness markets. They specialize in pharma-grade, food-grade, and feed-grade amino acids, custom blends, and high-purity formulations under strict regulatory standards. Although Ajinomoto is less known for classic IV fluid bags or large-volume saline in Saudi Arabia, their expertise in amino acids (used in parenteral nutrition, specialty injectables, or as components in complex IV formulations) gives potential for supplying raw ingredients, custom blends or specialized nutrition solutions in that market.
B. Braun SE
B. Braun is a German medical & pharmaceutical company, with a broad portfolio that includes infusion therapy, IV fluids and volume replacement, sterile containers, infusion sets, pumps, and irrigation solutions. In Saudi Arabia, B. Braun operates via local agents/distributors (e.g. Medical Supplies & Services Co. Ltd. / Mediserv) to bring its IV fluids, administration sets, and infusion technologies to hospitals and clinics. Their established product lines and regulatory compliance help them maintain presence in the Kingdom’s healthcare system where IV therapy and sterile infusions are in steady demand.
ICU Medical, Inc.
ICU Medical is a U.S.-based firm focused on devices and consumables around IV therapy: IV solutions, fluid administration sets, pumps, safety devices (e.g. needle-free connectors), etc. They manufacture IV solutions (including non-PVC/non-DEHP containers) in flexible packaging, and their portfolio supports both basic fluid administration and irrigations. While explicit Saudi Arabia operations are less well documented in public sources, ICU Medical is listed among key players in Saudi Arabia’s intravenous solutions market analyses, which suggests they are active through imports, distribution partnerships, or tenders supplying hospitals in the Kingdom.
Baxter AG
Baxter is a multinational healthcare company with broad operations in renal care, critical care, nutrition, IV & drug delivery, and hospital‐based therapies. In Saudi Arabia, Baxter is more deeply embedded: they set up Baxter Company Limited in a joint venture with Olayan Group, with a facility that manufactures both IV solutions and peritoneal dialysis fluids locally. That helps reduce reliance on imports and supports Saudi Arabia’s drive toward local pharmaceutical/medical supplies production under Vision 2030.
Other key players in the market include Fresenius Kabi AG, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd. and Vifor Pharma Management Ltd.
Saudi Arabia Intravenous Solution Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Key Market Trends and Insights
- Saudi Arabia contributed around 1.5% of the global intravenous solutions market revenue during the historical period.
- By nutrients, total parenteral nutrition emerged as the leading segment, representing nearly 68% of market revenue in the historical period.
- Salts and electrolytes are expected to lead the market by nutrients in the forecast period.
- Market Size (2024): USD 495.14 Million
- Projected Market Size (2034): USD 929.45 Million
- CAGR (2025-2034): 6.50%
The market is steadily evolving, supported by increasing hospital admissions, surgical procedures, and rising demand for advanced nutritional therapies. The market plays a modest yet important role globally, as Saudi Arabia contributed around 1.5% of the global intravenous solution market revenue during the historical period. The growing incidences of chronic illnesses, coupled with a higher prevalence of malnutrition in critically ill patients, are fueling demand for intravenous therapies. These factors are expected to strengthen market growth and enhance healthcare delivery outcomes. The market is expected to grow at a CAGR of 6.50% during the forecast period of 2025-2034 and attain a market value of USD 929.45 Million by 2034 .
Saudi Arabia Intravenous Solution Market Growth Drivers
Dedicated Infusion Clinics Bolstering Saudi Arabia IV Solution Market Expansion
Market drivers such as rising chronic disease rates and growing consumer wellness orientation are fueling demand for advanced IV therapies. For instance, in October 2024, IV ONE, Saudi Arabia’s first dedicated outpatient infusion therapy center, launched in Riyadh to serve chronic illness and nutrient-deficient patients. This facility offers personalized care delivered by specialists, integrated health systems, and faster clinical outcomes. Over the forecast period, this model is poised to elevate market value and adoption across the Kingdom by enhancing accessibility, improving treatment efficiency, and encouraging broader acceptance of intravenous solutions.
Saudi Arabia Intravenous Solution Market Trends
Major market trends include rise in foreign investments and emphasis on preventive healthcare adoption.
Foreign Investments Driving Saudi Arabia Intravenous Solution Market Growth
Rising healthcare infrastructure development and government support for local manufacturing are key drivers shaping the market. For instance, in January 2025, US-based Akkad Holdings announced a USD 200 million investment to establish an intravenous fluid production plant in King Abdullah Economic City, with operations expected after regulatory clearances within 18 months. This project, developed under Shamek IV Solutions, will address global IV shortages while boosting Saudi Arabia’s self-sufficiency and export capacity, significantly enhancing market growth prospects during the forecast period.
Rising Preventive Healthcare Focus Strengthening Saudi Arabia Intravenous Solution Market
The market is increasingly benefiting from the growing focus on preventive healthcare and wellness. With a rising prevalence of chronic diseases, nutritional deficiencies, and lifestyle-related conditions, demand for intravenous therapies is expanding beyond hospitals into outpatient and wellness settings. Consumers are adopting IV hydration and nutrient therapies for faster recovery, enhanced immunity, and preventive health maintenance. This shift toward proactive healthcare is expected to significantly drive market growth, broadening the application base for intravenous solutions in the forecast period.
Saudi Arabia Intravenous Solution Market Share
Total Parenteral Nutrition to Lead the Market by Type
Total parenteral nutrition is expected to hold the largest share of the Saudi Arabia intravenous solutions market, driven by its critical role in supporting patients unable to meet nutritional needs orally or enterally. It accounted for nearly 68% of market revenue during the historical period, underlining its dominance. The rising prevalence of chronic illnesses, surgical interventions, and malnutrition cases in hospitalized patients are further fueling demand. These factors position total parenteral nutrition as the primary growth driver across the country.
Leading Players in the Saudi Arabia Intravenous Solution Market
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Ajinomoto Health & Nutrition North America, Inc.
Ajinomoto Health & Nutrition is a division of the global Ajinomoto Group that develops, manufactures, and supplies amino acid-based products for pharmaceutical, nutraceutical, medical food, and wellness markets. They specialize in pharma-grade, food-grade, and feed-grade amino acids, custom blends, and high-purity formulations under strict regulatory standards. Although Ajinomoto is less known for classic IV fluid bags or large-volume saline in Saudi Arabia, their expertise in amino acids (used in parenteral nutrition, specialty injectables, or as components in complex IV formulations) gives potential for supplying raw ingredients, custom blends or specialized nutrition solutions in that market.
B. Braun SE
B. Braun is a German medical & pharmaceutical company, with a broad portfolio that includes infusion therapy, IV fluids and volume replacement, sterile containers, infusion sets, pumps, and irrigation solutions. In Saudi Arabia, B. Braun operates via local agents/distributors (e.g. Medical Supplies & Services Co. Ltd. / Mediserv) to bring its IV fluids, administration sets, and infusion technologies to hospitals and clinics. Their established product lines and regulatory compliance help them maintain presence in the Kingdom’s healthcare system where IV therapy and sterile infusions are in steady demand.
ICU Medical, Inc.
ICU Medical is a U.S.-based firm focused on devices and consumables around IV therapy: IV solutions, fluid administration sets, pumps, safety devices (e.g. needle-free connectors), etc. They manufacture IV solutions (including non-PVC/non-DEHP containers) in flexible packaging, and their portfolio supports both basic fluid administration and irrigations. While explicit Saudi Arabia operations are less well documented in public sources, ICU Medical is listed among key players in Saudi Arabia’s intravenous solutions market analyses, which suggests they are active through imports, distribution partnerships, or tenders supplying hospitals in the Kingdom.
Baxter AG
Baxter is a multinational healthcare company with broad operations in renal care, critical care, nutrition, IV & drug delivery, and hospital‐based therapies. In Saudi Arabia, Baxter is more deeply embedded: they set up Baxter Company Limited in a joint venture with Olayan Group, with a facility that manufactures both IV solutions and peritoneal dialysis fluids locally. That helps reduce reliance on imports and supports Saudi Arabia’s drive toward local pharmaceutical/medical supplies production under Vision 2030.
Other key players in the market include Fresenius Kabi AG, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd. and Vifor Pharma Management Ltd.
Saudi Arabia Intravenous Solution Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Partial Parenteral Nutrition
- Total Parenteral Nutrition
- Carbohydrates
- Salts and Electrolytes
- Minerals
- Vitamins
- Amino Acids
- Others
- Large Volume Bags (>250 mL)
- Small Volume Bags (<250 mL)
- Basic IV Solution
- Nutritional IV Solution
- Blood IV Solution
- Drug IV Solution
- Irrigation IV Solution
- Others
- Hospitals and Clincs
- Ambulatory Surgical Centers (ASCs)
- Homecare Settings
- Others
- What was the Saudi Arabia intravenous solution market value in 2024?
- What is the Saudi Arabia intravenous solution market forecast outlook for 2025-2034?
- What is the market breakup based on type?
- What is the market breakup based on nutrients?
- What is the market breakup based on the bag type?
- What is the market breakup based on the application?
- What are the major factors aiding the Saudi Arabia intravenous solution market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Saudi Arabia intravenous solution market trends?
- Which type will lead the market segment?
- Which nutrients will lead the market segment?
- Which bag type will lead the market segment?
- Which application will lead the market segment?
- Who are the key players involved in the Saudi Arabia intravenous solutions market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Intravenous Solution Market Overview
- 3.1 Middle East and Africa Intravenous Solution Market Overview
- 3.1.1 Middle East and Africa Intravenous Solution Market Historical Value (2018-2024)
- 3.1.2 Middle East and Africa Intravenous Solution Market Forecast Value (2025-2034)
- 3.2 Saudi Arabia Intravenous Solution Market Overview
- 3.2.1 Saudi Arabia Intravenous Solution Market Historical Value (2018-2024)
- 3.2.2 Saudi Arabia Intravenous Solution Market Forecast Value (2025-2034)
- 4 Saudi Arabia Intravenous Solution Market Landscape
- 4.1 Saudi Arabia Intravenous Solution Market: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Saudi Arabia Intravenous Solution Market: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Bag Type
- 4.2.3 Analysis by Nutrients
- 5 Saudi Arabia Intravenous Solution Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 PESTEL Analysis
- 5.3.1 Political
- 5.3.2 Economic
- 5.3.3 Social
- 5.3.4 Technological
- 5.3.5 Legal
- 5.3.6 Environment
- 5.4 Porter’s Five Forces Model
- 5.4.1 Bargaining Power of Suppliers
- 5.4.2 Bargaining Power of Buyers
- 5.4.3 Threat of New Entrants
- 5.4.4 Threat of Substitutes
- 5.4.5 Degree of Rivalry
- 5.5 Key Demand Indicators
- 5.6 Key Price Indicators
- 5.7 Industry Events, Initiatives, and Trends
- 5.8 Value Chain Analysis
- 6 Saudi Arabia Intravenous Solution Market Segmentation (218-2034)
- 6.1 Saudi Arabia Intravenous Solution Market (2018-2034) by Type
- 6.1.1 Partial Parenteral Nutrition
- 6.1.2 Total Parenteral Nutrition
- 6.2 Saudi Arabia Intravenous Solution Market (2018-2034) by Nutrients
- 6.2.1 Carbohydrates
- 6.2.2 Salts and Electrolytes
- 6.2.3 Minerals and Vitamins
- 6.2.4 Amino Acids
- 6.2.5 Others
- 6.3 Saudi Arabia Intravenous Solution Market (2018-2034) by Bag Type
- 6.3.1 Large Volume Bags (>250 mL)
- 6.3.2 Small Volume Bags (<250 mL)
- 6.4 Saudi Arabia Intravenous Solution Market (2018-2034) by Application
- 6.4.1 Basic IV Solution
- 6.4.2 Nutritional IV Solution
- 6.4.3 Blood IV Solution
- 6.4.4 Drug IV Solution
- 6.4.5 Irrigation IV Solution
- 6.4.6 Others
- 6.5 Saudi Arabia Intravenous Solution Market (2018-2034) by End User
- 6.5.1 Hospitals and Clincs
- 6.5.2 Ambulatory Surgical Centers (ASCs)
- 6.5.3 Homecare Settings
- 6.5.4 Others
- 7 Regulatory Framework
- 8 Funding and Investment Analysis
- 8.1 Analysis by Funding Instances
- 8.2 Analysis by Type of Funding
- 8.3 Analysis by Funding Amount
- 8.4 Analysis by Leading Players
- 8.5 Analysis by Leading Investors
- 8.6 Analysis by Geography
- 9 Strategic Initiatives
- 9.1 Analysis by Partnership Instances
- 9.2 Analysis by Type of Initiatives
- 9.3 Analysis by Leading Players
- 9.4 Analysis by Geography
- 10 Supplier Landscape
- 10.1 Vendor Positioning Analysis
- 10.1.1 Key Vendors
- 10.1.2 Prospective Leaders
- 10.1.3 Niche Leaders
- 10.1.4 Disruptors
- 10.2 Market Share Analysis (Top 5 Companies)
- 10.3 Ajinomoto Health & Nutrition North America, Inc.
- 10.3.1 Financial Analysis
- 10.3.2 Product Portfolio
- 10.3.3 Demographic Reach and Achievements
- 10.3.4 Company News and Developments
- 10.3.5 Certifications
- 10.4 B. Braun SE
- 10.4.1 Financial Analysis
- 10.4.2 Product Portfolio
- 10.4.3 Demographic Reach and Achievements
- 10.4.4 Company News and Developments
- 10.4.5 Certifications
- 10.5 ICU Medical, Inc.
- 10.5.1 Financial Analysis
- 10.5.2 Product Portfolio
- 10.5.3 Demographic Reach and Achievements
- 10.5.4 Company News and Developments
- 10.5.5 Certifications
- 10.6 Baxter AG
- 10.6.1 Financial Analysis
- 10.6.2 Product Portfolio
- 10.6.3 Demographic Reach and Achievements
- 10.6.4 Company News and Developments
- 10.6.5 Certifications
- 10.7 Fresenius Kabi AG
- 10.7.1 Financial Analysis
- 10.7.2 Product Portfolio
- 10.7.3 Demographic Reach and Achievements
- 10.7.4 Company News and Developments
- 10.7.5 Certifications
- 10.8 Pfizer Inc.
- 10.8.1 Financial Analysis
- 10.8.2 Product Portfolio
- 10.8.3 Demographic Reach and Achievements
- 10.8.4 Company News and Developments
- 10.8.5 Certifications
- 10.9 Otsuka Pharmaceutical Co., Ltd.
- 10.9.1 Financial Analysis
- 10.9.2 Product Portfolio
- 10.9.3 Demographic Reach and Achievements
- 10.9.4 Company News and Developments
- 10.9.5 Certifications
- 10.10 Vifor Pharma Management Ltd.
- 10.10.1 Financial Analysis
- 10.10.2 Product Portfolio
- 10.10.3 Demographic Reach and Achievements
- 10.10.4 Company News and Developments
- 10.10.5 Certifications
- 11 Saudi Arabia Intravenous Solution Market – Distribution Model (Additional Insight)
- 11.1 Overview
- 11.2 Potential Distributors
- 11.3 Key Parameters for Distribution Partner Assessment
- 12 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
